Alzheimer's Disease Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person joining must sign an informed consent form agreeing to take part.
- People who are able to lie still inside an MRI scanner for at least one hour.
- People with no current or past history of drug or alcohol abuse.
- People who are not taking any medications that interfere with thinking or memory.
- People with normal vision, or vision that can be fully corrected with glasses or contact lenses.
For the Type 2 Diabetes group specifically:
- People who have been diagnosed with Type 2 diabetes according to standard medical guidelines.
- People whose diabetes is managed through lifestyle changes and/or non-insulin medications.
For the Carotid Stenosis group specifically:
- People who have a narrowing of 50% or more in one of their carotid arteries (the main arteries in the neck that supply blood to the brain).
For the Mild Cognitive Impairment or Alzheimer's Disease group specifically:
- People who have been diagnosed with mild cognitive impairment or early-stage Alzheimer's disease.
- People between the ages of 60 and 80 years.
- People who are fluent in German.
- People with normal vision and hearing, or vision and hearing that can be fully corrected.
- People who are able to understand the research and provide informed consent.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People under 18 years of age.
- People who experience claustrophobia (fear of enclosed spaces).
- People who are currently pregnant or breastfeeding.
- People who have active implanted medical devices, such as pacemakers or nerve stimulators.
- People who have passive implants made of magnetic (ferromagnetic) metal inside their body.
- People who have passive non-magnetic metal implants larger than 4 cm in an area that would be covered by the MRI scanning equipment.
- People with large tattoos in areas of the body that would be covered by the MRI scanning equipment.
- People who are unlikely to follow the study rules or complete the study as required.
- People weighing less than 30 kg.
- People with a Body Mass Index (BMI) over 30 (a measure of body weight relative to height).
- People weighing more than 135 kg.
- People with an unusually large head size or a severe eye condition (astigmatism) that cannot be corrected with MRI-compatible glasses.
- People who are not able to understand the informed consent form.
- People who do not agree to be informed if something unexpected is found during their scan.
- People whose vision or hearing is poor enough to interfere with the thinking and memory tests used in the study (where relevant).
- People who have diabetes or difficulty processing blood sugar (excluding those enrolled in the diabetes group).
- People who show signs of significant heart or kidney disease.
- People who show signs of disease in the digestive system.
- People with signs of thinking or memory difficulties, as measured by standard tests — excluding those in the Alzheimer's or mild cognitive impairment group (confirm with trial site).
- People who currently smoke.
- People with current or past drug or alcohol abuse.
- People with untreated high cholesterol, high blood pressure, or thyroid disease.
- People taking antidepressant medications that have anticholinergic properties (a type of side effect that can affect memory and thinking — confirm with trial site).
- People who regularly use narcotic (strong painkiller) medications more than twice a week within the four weeks before screening.
- People who have taken Parkinson's disease medications within four weeks before screening.
- People who have taken part in another clinical drug trial within four weeks before screening.
- People currently receiving treatment that affects the immune system or treatment for cancer.
- People who have a cardiac implantable electronic device, such as a pacemaker, implantable defibrillator, or cardiac resynchronisation therapy device.
- People who may have metal fragments in or near their eyes — for example, those who have ever welded without eye protection or had facial injuries involving metal (an x-ray review by a radiologist would be required before an MRI could be done).
- People who have an implanted nerve stimulation system.
- People who have cochlear implants or other ear implants.
- People who have an implanted drug delivery pump, such as for insulin, painkillers, or chemotherapy.
- People who have a catheter with metal components inside their body.
- People who have metal fragments in their body, such as bullets, pellets, or shrapnel.
- People who have surgical clips on a brain artery (cerebral aneurysm clips).
- People who have magnetic dental implants.
- People who have tissue expanders implanted in their body.
- People who have artificial limbs.
- People who wear non-removable hearing aids.
- People who wear non-removable piercings.
- People who have a fever (body temperature above 37.5°C) at the time of their MRI.
- People who are taking amphetamines or sedative medications.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Johannes Slotboom, PhD, University Hospital / Inselspital /University Bern / 3010 Bern / Switzerland
Phone: +41316327469
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
3D spatial resolved Deuterium metabolite imaging (DMI); 3D spatial resolved SLOW-EPSI MRSI metabolite mapping; 3D spatial resolved 3D DMI and 3D SLOW-EPSI MRSI mapping in Alzheimer's disease (AD) patient group; 3D spatial resolved 3D DMI and 3D SLOW-EPSI MRSI mapping in Mild Cognitive Impairment (MCI) patient group; 3D DMI and 3D SLOW-EPSI MRSI mapping in a Diabetes Mellitus (DM) Type II patient group; 3D DMI and 3D SLOW-EPSI MRSI mapping in a High Grade Carotid Stenosis (HGCS) patient group
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.